Psoriasis is one of the most common chronic inflammatory skin diseases, affecting about 250,000 people in Austria. While ...
Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
First for Women on MSN10d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Medical University of Vienna. (2025, March 3). New treatment option for psoriasis discovered. ScienceDaily. Retrieved March 14, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250303141858.htm ...
Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...
Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
"Psoriasis can be a challenging condition to manage due to long-term treatments with various side effects. SFA-002's effect in the imiquimod-induced mouse model is compelling. The results ...
The latest news from AAD 2025 focused on psoriasis including abstracts, features, and helpful conference information.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback